Table 4 Factors of dementia among different models using Cox regression and the Fine–Gray competing risk model

Sulfadiazine

With toxoplasmosis, without sulfadiazine

5

1015.10

492.56

Reference

With toxoplasmosis, with sulfadiazine

16

3571.66

447.97

0.909

0.887

0.932

0.013

With toxoplasmosis, with sulfadiazine < 30 days

5

1047.15

477.48

0.967

0.943

0.991

0.046

With toxoplasmosis, with sulfadiazine 30–364 days

5

1257.18

397.72

0.808

0.782

0.845

 < 0.001

With toxoplasmosis, with sulfadiazine ≥ 365 days

6

1267.33

473.44

0.932

0.901

0.986

0.041

Clindamycin

With toxoplasmosis, without clindamycin

5

879.28

568.65

Reference

With toxoplasmosis, with clindamycin

16

3707.48

431.56

0.759

0.732

0.797

 < 0.001

With toxoplasmosis, with clindamycin < 30 days

5

1048.48

476.88

0.832

0.784

0.863

 < 0.001

With toxoplasmosis, with clindamycin 30–364 days

5

1056.84

473.11

0.821

0.776

0.859

 < 0.001

With toxoplasmosis, with clindamycin ≥ 365 days

6

1602.17

374.49

0.664

0.602

0.692

 < 0.001

Sulfadiazine

With toxoplasmosis, without antibiotics

1

198.15

504.67

Reference

and / or

With toxoplasmosis, with any antibiotics

20

4388.61

455.72

0.927

0.894

0.950

0.022

Clindamycin

With toxoplasmosis, with any antibiotics < 30 days

5

1030.45

485.22

0.970

0.942

0.995

0.047

With toxoplasmosis, with any antibiotics 30–364 days

7

1544.20

453.31

0.965

0.931

0.983

0.041

With toxoplasmosis, with any antibiotics ≥ 365 days

8

1813.96

441.02

0.864

0.803

0.899

 < 0.001

With toxoplasmosis, with both antibiotics

12

2890.53

415.15

0.812

0.694

0.872

 < 0.001

With toxoplasmosis, with both antibiotics < 30 days

5

1065.18

469.40

0.853

0.793

0.901

 < 0.001

With toxoplasmosis, with both antibiotics 30–364 days

3

769.82

389.70

0.750

0.615

0.830

 < 0.001

With toxoplasmosis, with both antibiotics ≥ 365 days

4

1055.54

378.95

0.721

0.594

0.825

 < 0.001